Health and Healthcare

BioMarin : BMRN

All BioMarin Articles

169 Articles

Lee Jackson | Feb 3, 2015 at 9:25 AM EST

Portfolio Managers Love These 5 Biotech Stocks

Here are the five biotech stocks that are loved the most by portfolio managers, according to Cowen analysts.

Jon C. Ogg | Jan 8, 2015 at 8:40 AM EST

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, ADM, BofA, Chesapeake, Google, J.P. Morgan, MGM and More

Thursday's top analyst upgrades, downgrades and initiations seen from Wall Street research calls includes Alcatel-Lucent, ADM, Bank of America, Chesapeake…

Chris Lange | Jan 7, 2015 at 2:51 PM EST

Wells Fargo’s Top Biotech Stocks for 2015

ThinkstockLooking back at 2014, biotechs had a phenomenal year, and this looks to continue into 2015. The NYSE Arca Biotech…

Jon C. Ogg | Dec 30, 2014 at 7:45 AM EST

The Best Performing Biotech Stocks of 2014: Amazing 300% Gainers

Out of 28 biotech stocks with market capitalization rates north of $300 million that were up 100% or more in…

Lee Jackson | Dec 23, 2014 at 9:50 AM EST

RBC’s 5 Top Biotech Stocks to Buy for 2015

One sector that could be poised to do well could be the biotech arena, and the team at RBC has…

Lee Jackson | Nov 25, 2014 at 8:40 AM EST

RBC Has Three Top Biotech Picks for Year End and 2015

ThinkstockIf any sector has had an up and down 2014, it would be the biotech. A massive sell-off in the…

Chris Lange | Nov 24, 2014 at 9:15 AM EST

Big News for Ebola Stocks

Monday may have started out as a fairly quiet news day for most stock sectors on a shortened week, but…

Jon C. Ogg | Nov 10, 2014 at 8:45 AM EST

Top Analyst Upgrades and Downgrades: BioMarin, BP, Genworth, Petrobras, Target and More

Monday's top analyst upgrades, downgrades and initiations include BioMarin Pharmaceutical, BP, Home Depot, Petrobras and Target.

Lee Jackson | Sep 25, 2014 at 8:35 AM EDT

5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential

For many of the top biotech companies, orphan drugs have morphed into huge winners and have even generated other streams…

Chris Lange | Sep 3, 2014 at 11:50 AM EDT

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm.

Lee Jackson | Jul 18, 2014 at 9:15 AM EDT

Analyst Issues Top Biotech Stocks to Buy Ahead of Earnings

ThinkstockFor the third time in less than two weeks, one of the top brokerage firms we cover at 24/7 Wall Street…

Lee Jackson | Jul 9, 2014 at 8:40 AM EDT

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

In a new research report, UBS analysts are very positive on some top biotech stocks before second-quarter earnings numbers hit…

Lee Jackson | Jul 3, 2014 at 8:40 AM EDT

J.P. Morgan’s Top Stock Picks for the Second Half of 2014

A new report from the equity strategy team at J.P. Morgan presents an extensive list of top names to buy…

Jon C. Ogg | Jun 12, 2014 at 8:30 AM EDT

Top Analyst Upgrades and Downgrades: Apache, Apple, HP, Qualcomm, Sprouts and More

These are the top Wall Street analyst upgrades, downgrades and initiations for Thursday, June 12, 2014. They include Apache, Apple,…

Jon C. Ogg | May 16, 2014 at 8:30 AM EDT

Top Biotech Stocks for Cancer Cures From Cowen

ThinkstockThe conference season is starting to get into full swing, and for the top biotech stocks, that means an appearance…

1 … 7 8 9 10 11 12

BioMarin : BMRN

All BioMarin Articles

Portfolio Managers Love These 5 Biotech Stocks

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, ADM, BofA, Chesapeake, Google, J.P. Morgan, MGM and More

Wells Fargo’s Top Biotech Stocks for 2015

The Best Performing Biotech Stocks of 2014: Amazing 300% Gainers

RBC’s 5 Top Biotech Stocks to Buy for 2015

RBC Has Three Top Biotech Picks for Year End and 2015

Big News for Ebola Stocks

Top Analyst Upgrades and Downgrades: BioMarin, BP, Genworth, Petrobras, Target and More

5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

Analyst Issues Top Biotech Stocks to Buy Ahead of Earnings

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

J.P. Morgan’s Top Stock Picks for the Second Half of 2014

Top Analyst Upgrades and Downgrades: Apache, Apple, HP, Qualcomm, Sprouts and More

Top Biotech Stocks for Cancer Cures From Cowen

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

BioMarin : BMRN

All BioMarin Articles

Portfolio Managers Love These 5 Biotech Stocks

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, ADM, BofA, Chesapeake, Google, J.P. Morgan, MGM and More

Wells Fargo’s Top Biotech Stocks for 2015

The Best Performing Biotech Stocks of 2014: Amazing 300% Gainers

RBC’s 5 Top Biotech Stocks to Buy for 2015

RBC Has Three Top Biotech Picks for Year End and 2015

Big News for Ebola Stocks

Top Analyst Upgrades and Downgrades: BioMarin, BP, Genworth, Petrobras, Target and More

5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

Analyst Issues Top Biotech Stocks to Buy Ahead of Earnings

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

J.P. Morgan’s Top Stock Picks for the Second Half of 2014

Top Analyst Upgrades and Downgrades: Apache, Apple, HP, Qualcomm, Sprouts and More

Top Biotech Stocks for Cancer Cures From Cowen

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

Featured Reads

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not